Views | |
---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 152 |
March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | August 2024 | September 2024 | |
---|---|---|---|---|---|---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 3 | 0 | 4 | 1 | 13 | 9 | 3 |
Views | |
---|---|
2021_Frost_etal.pdf | 200 |